Global Payments Leader, Credorax, Rebrands As ‘Finaro’
1.12.2021 19:03:00 EET | Business Wire | Press release
Leading smart payments provider and merchant acquiring bank, Credorax, has today announced its new company identity, Finaro .
Focusing on its core pillars of creating multi-dimensional solutions to simplify payments and going the extra mile for its merchants, Finaro empowers global commerce by providing the ideal solution for cross-border businesses with its cutting-edge technology and superior support.
The news of the rebranding bookends a strong 2021, with Finaro’s impressive 40% Year-on-Year Compound Annual Growth Rate. Founded in 2009, the company currently employs over 350 people, and is based in Israel and Malta, with presence in China Mainland, Hong Kong, the United States and across Europe.
Credorax has already been proven as a payments provider that facilitates its merchants’ growth and with the global fintech industry expected to skyrocket to $190bn by 2026, this rapidly accelerating trajectory creates the perfect environment for Finaro’s new brand to establish itself as a strong player amongst its peers. This huge growth in fintech has seen cross-border sales take more than a quarter of the entire ecommerce marketplace in Europe, highlighting the significance of a provider that can make multidimensional payments brilliantly simple.
Finaro serves over 5000 merchants around the world and in a wide variety of industries, including retail, digital goods and services, travel, hospitality, and mobility. Kiwi.com, Air Baltic, Wolt, Payrexx, Revolut, Go2Mobile and Hero Gaming are among its customers and across all verticals the trend is similar: all merchants are operating within very competitive markets and they are required to create perfect customer experiences. Led by a team of payments experts and solution-creators, Finaro is committed to absorbing the immense complexity of payments and delivering simplicity, so merchants are free to pursue their ambition, knowing they are covered.
“Our company success has always been built on our in-house, cutting-edge full stack platform as well as strong customer relationships, and constant product innovation. Our passionate team of solutions-creators with a can-do approach enable us to create brilliantly simple payment solutions for our merchants, said Igal Rotem, Chief Executive Officer for Finaro.
“Our evolution from Credorax to Finaro reflects the revolution our business has undertaken since joining the payments world 15 years ago and our rebranding is the next step in our growth as a company and on our path towards realizing our vision of commerce, untethered. I’m incredibly proud reveal our new brand identity as Finaro,” Igal continued.
“We came into this industry with a fresh view because we saw obstacles that needed getting beyond, and that’s what we have been doing ever since,” commented Moshe Selfin, Chief Operating & Chief Technology Officer for Finaro. “We pioneered a multidimensional approach to payments that untangles even the most wicked problems in the payments space, paving the way for new and exciting possibilities and giving our merchants a meaningful competitive advantage.”
“Branding is much more than just colours, logos and slogans - it’s about the essence of our company and how we are presented to the world externally. When developing our new brand Finaro, we crystalized our essence, and it was critical to establish our identity as a company that cares about its customers and can deliver the outstanding,” explains Achiya Fried, Chief Commercial Officer of Finaro, “We go the extra mile in flexibility and we co-create solutions with our clients, by providing cutting edge, multidimensional payments solutions, that untangle the complexity of payments. Our new brand, Finaro, reflects just that."
###ENDS###
About Finaro
Finaro is a global cross-border payment provider empowering international commerce through brilliantly simple payments. Our passionate team, exceptional tech capabilities, product innovation, and customer-centric approach enables us to simplify complexity and create multidimensional solutions that generate growth and enable peace of mind for our merchants. To learn more, visit www.finaro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005805/en/
Contact information
Jenna Walker
jenna@skyparlour.com
07591 382 856
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla to Meet With Mobile Game Developers and Publishers at Pocket Gamer Connects Barcelona 202611.6.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced its participation in Pocket Gamer Connects (PGC) Barcelona 2026, taking place June 15-16 at the Hyatt Regency Barcelona in Barcelona, Spain. Xsolla will be on the ground for meetings with mobile game developers, publishers, and strategic partners, bringing its direct-to-consumer commerce infrastructure to one of the most deal-focused events in the European games calendar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611487209/en/ Graphic: Xsolla Now in its second year, PGC Barcelona has quickly established itself as a destination conference for mobile game businesses, drawing more than 1,000 attendees from over 47 countries and facilitating thousands of structured business meetings through its dedicated matchmaking platform. Barcelona itself has become one of Europe's most significant gaming cities, home to studios including Scopely, King, Rovio, Band
Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.11.6.2026 16:00:00 EEST | Press release
Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2026 conference. The medtech company will showcase this innovative solution at booth #600 during the largest annual sleep medicine conference, which brings together leading experts and innovators in the field. Furthermore, in anticipation of new CPT codes, Onera Health will host an educational symposium on Scaling PSG for the Next Decade: Expanding Utilization of High-Complexity Home Testingon Monday, June 15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611302332/en/ Onera hPSG® – Bringing PSG Home. “We are excited to see our Onera hPSG® solution highlighted at this important meeting in three different presentations and an educational seminar. Onera hPSG® is positioned to be an integral par
IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 15:50:00 EEST | Press release
The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The installation, located at the CINECA headquarters in the DAMA Tecnopolo in Bologna, represents not just technological progress but a strategic Italian asset providing concrete tools for the scientific community and businesses to foster innovation, accelerate research, and transform knowledge into high-impact applications.
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
